Comments on the potential abuse and medical usefulness of a range of substances including CBD will be submitted to the World Health Organization (WHO) by the US Food and Drug Administration (FDA) and its parent government department.

The comments will be used by the WHO to determine recommendations on international restrictions for 16 substances. They include cannabis plants and resin as well as extracts and tinctures of cannabis, which would include CBD, as well as THC and related compounds.

In order to develop its response, the FDA is currently requesting informed comments, which should be submitted by the end of October.

Comments received by the FDA and the US Department of Health and Human Services (HHS) will be considered by the HHS in preparing a scientific and medical evaluation for drug substances to be forwarded to the WHO.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us